He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types. Coverage brought to you by

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...

Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.

Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.